Targeted Gene Sequencing Transforms Molecular Diagnosis of Hereditary Hemochromatosis

Hereditary hemochromatosis has long been one of medicine’s deceptively simple puzzles. Patients accumulate iron because their bodies fail to regulate absorption properly, and over years the metal quietly builds up in the liver, heart, pancreas, and joints. Yet behind this seemingly straightforward pathology lies a maze of genes, variants, and phenotypes that frequently confounds diagnosis. A new study from a Greek research team, published in Annals of Hematology, argues that the way forward runs through targeted next-generation sequencing combined with sophisticated structural modeling of the very proteins that misbehave.

The research, led by Vasiliki Galani and Matthaios Speletas of the University of Thessaly together with collaborators from Papageorgiou General Hospital in Thessaloniki, applied a targeted sequencing panel covering twelve genes implicated in hereditary hemochromatosis and in iron homeostasis more broadly. Rather than screening only the classic HFE gene, which accounts for the majority of cases in populations of Northern European descent, the panel interrogated the wider genetic landscape of iron metabolism, including genes such as HJV, HAMP, TFR2, SLC40A1, and ERFE. This broader approach reflects a growing recognition that non-HFE forms of the disease, though individually rare, collectively represent a meaningful share of patients, particularly in Mediterranean populations where variant distributions differ from the Northern European canon.

Technically, the workflow was deliberately conservative and rigorous. Sequencing results were interpreted according to the guidelines of the American College of Medical Genetics and Genomics, the standard framework that classifies variants into five tiers ranging from benign to pathogenic. Every finding was then confirmed by conventional PCR followed by Sanger sequencing, the older but highly accurate method that remains the gold standard for validating individual variants called by high-throughput platforms. This two-step strategy guards against false positives, an ever-present concern when sequencing pipelines involve enzymatic amplification, alignment algorithms, and variant-calling software that can each introduce artifacts.

The clinical payoff of this approach was illustrated by a case supporting a diagnosis of juvenile hemochromatosis, the aggressive early-onset form of the disease caused by mutations in genes such as HJV and HAMP. The team identified the established pathogenic HJV p.Gly320Val variant, a well-characterized substitution that swaps a glycine for a valine at position 320 of the hemojuvelin protein. Juvenile hemochromatosis typically manifests before the age of thirty, with severe iron loading, cardiomyopathy, hypogonadism, and endocrine damage, and it behaves very differently from the adult HFE-related form. Distinguishing it early is not an academic exercise: therapeutic intensity, family screening, and monitoring schedules all hinge on knowing which genetic subtype a patient carries.

Perhaps the most scientifically intriguing finding was an ultra-rare variant of uncertain significance in the ERFE gene, designated c.478G>A, or p.Ala160Thr. ERFE encodes erythroferrone, a hormone produced by developing red blood cells that suppresses hepcidin, the master hormonal regulator of iron absorption and release. The variant is so rare that existing databases and literature provide no evidence about its clinical consequences, which is precisely why it falls into the variant of uncertain significance category. Faced with such ambiguity, the researchers turned to structural biology, using AlphaFold3 to model the three-dimensional consequences of the amino acid substitution and visualizing the results in PyMOL.

The structural modeling suggested that the p.Ala160Thr substitution could potentially alter properties that affect protein function, though the investigators were careful to frame this as suggestive rather than conclusive. This is where the study touches on one of the liveliest debates in modern genomics: what to do with variants of uncertain significance. Returning an ambiguous result to a patient can create anxiety and, in the worst case, misdirect clinical decisions. But dismissing such variants outright risks missing genuine disease causes. The Greek team’s approach, pairing sequencing with protein structural prediction, offers a middle path, generating mechanistic hypotheses that can guide future functional studies without overclaiming pathogenicity in the present.

A third finding served as an internal quality control rather than a clinical discovery. The established pathogenic SLC40A1 p.Arg178Gln variant, affecting the ferroportin iron exporter, was detected in a control sample. Far from undermining the study, this observation validated the robustness of the methodology, demonstrating that the panel reliably detects known pathogenic variants even in individuals who were not the primary subjects of investigation. Quality assurance of this kind matters enormously in clinical genomics, where a missed variant can mean a missed diagnosis and a delayed intervention for a family member who has inherited the same mutation.

The broader context of the work is the steady migration of hemochromatosis diagnostics from single-gene testing toward comprehensive molecular panels. Historically, diagnosis relied on a combination of transferrin saturation, serum ferritin, and HFE genotyping, which works reasonably well for the common C282Y homozygous genotype but fails patients with rarer genetic architectures. Patients with unexplained hyperferritinemia, a common clinical referral trigger, frequently cycle through liver biopsies, imaging studies, and repeat blood tests without ever receiving a molecular answer. A twelve-gene panel collapses this diagnostic odyssey into a single assay, and the authors argue that this, in turn, enables more personalized management strategies tailored to the specific genetic defect underlying each patient’s iron overload.

There are limits worth acknowledging. AlphaFold3’s predictions describe protein structure, not function, and a plausible structural perturbation does not prove that a variant disrupts erythroferrone signaling in living cells. Functional assays, segregation studies in families, and accumulation of additional cases will be needed to reclassify variants like ERFE p.Ala160Thr. Nonetheless, the study offers a template for how clinical genetics laboratories can responsibly handle uncertainty: sequence broadly, interpret under established frameworks, confirm rigorously, and use structural modeling to add a layer of mechanistic plausibility without overstating the evidence. As sequencing costs continue to fall and structural prediction tools grow more accurate, that template may well become the standard against which iron disorder diagnostics are measured, converting a historically underdiagnosed condition into one where the genetic answer, more often than not, is within reach.

Subject of Research: Targeted next-generation sequencing for the molecular diagnosis of hereditary hemochromatosis

Article Title: Targeted next-generation sequencing in the molecular diagnosis of hereditary hemochromatosis

Article References: Galani, V., Apostolou, C., Kalala, F., Galanopoulos, A. P., Sarrou, S., Papchianou, E., Matziri, A., Gkousiaris, D. F., Zachou, K., Dalekos, G., Hadjichristodoulou, C., Kioumi, A., & Speletas, M. (2026). Targeted next-generation sequencing in the molecular diagnosis of hereditary hemochromatosis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07269-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07269-6

Keywords: hereditary hemochromatosis, next-generation sequencing, juvenile hemochromatosis, HJV, ERFE, erythroferrone, SLC40A1, variants of uncertain significance, AlphaFold3, iron metabolism, genetic diagnostics, hyperferritinemia